exhibit 10. 01 exhibit 10. 01 license and access agreement by and between start fresh recovery, inc. and fresh start private management inc. this license and access agreement ( the “ agreement ” ) entered into as of october 2, 2013 is between start fresh recovery, inc., a california professional medical corporation ( “ medical group ” ) and fresh start private management inc., a california corporation ( “ fresh start ” ). recitals. whereas, trinity rx solutions, llc has developed and owns and / or otherwise possesses [ exclusive ] intellectual property, proprietary and other rights and know - how in a long - acting naltrexone implant product ( defined below ) which, when administered by a licensed physician, may reduce alcohol cravings in individuals for up to twelve months or more ; whereas, educational information and treatment results from appropriate health care professionals and from substance abuse counselors employing alcohol addiction counseling programs, communication skills, techniques and assessment and case management protocols developed by fresh start, in whole or in part, outside of the united states ( collectively, the “ counseling program ” ) have shown positive results when individuals both ( a ) receive an administration of the long - acting naltrexone implant product from their treating physicians, and ( b ) participate in the counseling program which is aimed at bringing about behavioral changes while alcohol cravings are being reduced by the naltrexone implant product ; whereas, trinity rx solutions has developed relationships with one or more independent compounding pharmacies which trinity rx solutions has trained and granted exclusive rights to make the proprietary naltrexone implant product ( the “ licensed compounding pharmacies ” ), a current list of which is attached hereto as exhibit a ; whereas, trinity rx solutions has entered into a licensing agreement with fresh start pursuant to which fresh start has been granted an exclusive license and rights to provide physicians and physician groups with access to and the right to purchase the naltrexone implant product from a licensed compounding pharmacy ; whereas, medical group has been and is engaged in the treatment of patients for alcohol addiction in the territory ( defined below ) ; and whereas, medical group desires to obtain from fresh start access to the naltrexone implant product for the treatment of medical group ’ s patients when medical group, in its sole discretion, determines that such treatment is medically indicated and appropriate for particular patients, access to educational resources ( defined below ) and access and the counseling program which